- Angiosarcoma treatment encompasses a range of therapeutic approaches aimed at managing this rare and aggressive cancer, with chemotherapy, radiation therapy, and targeted drug therapies being the primary modalities used across various healthcare settings to improve survival and quality of life
- The increasing prevalence of soft tissue sarcomas, enhanced awareness about rare cancers, and growing emphasis on early detection and precision medicine are driving the demand for advanced angiosarcoma treatments globally
- North America dominated the angiosarcoma treatment market with the largest revenue share of 42.5% in 2024, supported by well-established healthcare infrastructure, high diagnostic rates, and strong research funding, particularly in the U.S., where increased clinical trial activity and the adoption of novel targeted therapies are accelerating patient access to effective treatment options
- Asia-Pacific is expected to be the fastest growing region in the angiosarcoma treatment market during the forecast period due to improving cancer care facilities, rising healthcare spending, and increasing focus on rare disease management across developing nations
- The chemotherapy segment dominated the angiosarcoma treatment market with a market share of 45.1% in 2024, driven by its broad applicability, availability, and integration with combination therapy regimens used in both early-stage and metastatic cases
